DCM
AGIO icon

Defilade Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Defilade Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Buy
+546,848
New +$16.6M 2.72% 16

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Defilade Capital Management's AGIO Position: Q2 2026 in Review

Defilade Capital Management opened a new position in Agios Pharmaceuticals (AGIO) in Q2 2026: 546,848 shares worth $20.3M. The stake represents 2.72% of the portfolio and ranks #16 among its holdings.

238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Defilade Capital Management held 546,848 shares of Agios Pharmaceuticals worth $20.3M as of Q2 2026.
  • Agios Pharmaceuticals was a new Defilade Capital Management position in Q2 2026.
  • Agios Pharmaceuticals made up 2.72% of Defilade Capital Management's portfolio in Q2 2026, its #16 holding.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.